Sunday 18 October 2026 Export EYPT’s income statement to Excel — free account

EyePoint, Inc.

EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.00 0.14 −4.46%

Follow EYPT

Alert me

Market cap: $270.7M
P/E: 0.0×
Fwd P/E: −3.3×
Dividend yield: —
F-score: 3/9
Altman Z: 8.46
Beneish M: −2.16
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.07

Total sells 2.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	1	—	—
Sell	2	2	1	1	1	1	—	1	—	—	—	—

Insider Ownership 6.74%

Capital & Financial Ratios $m

Market Cap 270.71

Revenue 2.79

Net Income (306.64)

Free Cash Flow (271.12)

Net Debt (180.47)

Current Ratio 4.50

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.33)

P/S ratio 93.12

P/B ratio 1.56

Past 5Y EPS Growth —

This Y EPS Growth (17.31%)

Next Y EPS Growth 26.66%

Next Y revenue growth (94.64%)

Next 5Y EPS Growth 19.87%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.91%

10-year low 10-year high

P/B against its own 10 years 8.00%

10-year low 10-year high

EV/Sales against its own 10 years 86.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	331	371	306	180
Receivables	1	1	1	0
Inventory	4	2	2	2
Other	—	—	—	—
	345	383	329	189

	2023	2024	2025	Q'26
Payables	7	12	10	17
ST’ Debt	—	—	—	—
Other	—	—	—	—
	63	49	37	42

Compound Annual Growth %

	10y	5y	3y
Sales	15.32%	(1.85%)	(8.83%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	36.80%	75.21%	47.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	24	5	1	1	31
’24	12	9	11	12	43
’23	8	9	15	14	46
’22	9	12	10	11	41
’21	7	9	9	12	37
’20	7	4	16	7	34

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(81)	(62)	—	—	—
’25	(53)	(63)	(59)	(65)	(240)
’24	(31)	(20)	(39)	(36)	(126)
’23	(17)	57	(15)	(23)	2
’22	(20)	(19)	(13)	(13)	(65)
’21	(15)	(11)	(8)	(17)	(50)
’20	(16)	(5)	1	6	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(64)	—	—	—
’25	(53)	(64)	(60)	(66)	(243)
’24	(32)	(21)	(41)	(36)	(130)
’23	(17)	57	(17)	(24)	(2)
’22	(20)	(19)	(14)	(13)	(67)
’21	(15)	(11)	(8)	(17)	(50)
’20	(16)	(5)	1	6	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.99)	(1.09)	—	—	—
’25	(0.65)	(0.85)	(0.85)	(0.81)	(3.17)
’24	(0.55)	(0.58)	(0.54)	(0.64)	(2.32)
’23	(0.56)	(0.61)	(0.33)	(0.33)	(1.82)
’22	(0.56)	(0.52)	(0.49)	(1.16)	(2.74)
’21	(0.50)	(0.35)	(0.58)	(0.59)	(2.03)
’20	(1.10)	(1.00)	(0.30)	(1.07)	(3.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	15.00	10.20	9.30	11.90	3.50	6.87	2.19	2.21	6.90	3.91	Analyst estimates 2026–2028 Powerpack
	High	48.20	24.50	39.40	28.20	21.00	21.50	14.41	24.62	30.99	19.11
People
People	Employees	20	22	44	84	101	123	144	121	165	214
	Revenue/emp, $m	0.00	0.00	0.00	0.24	0.34	0.30	0.29	0.38	0.26	0.15
Income, $m
Income, $m	Revenue	2	8	6	20	34	37	41	46	43	31
	Gross margin, %	0.00	89.19	0.00	86.81	83.09	77.86	79.89	89.93	91.42	93.41
	EBT	(22)	(18)	(89)	(57)	(45)	(58)	(102)	(71)	(131)	(232)
	EBT margin, %	(1,349.44)	(245.19)	(1,527.32)	(278.88)	(131.82)	(158.14)	(246.97)	(153.66)	(302.22)	(738.53)
	Net income	(22)	(18)	0	(57)	(45)	(58)	(102)	(71)	(131)	(232)
	Depreciation	1	1	1	3	3	3	23	0	(4)	(3)
Per share, $
Per share, $	Revenue	0.51	2.13	0.69	1.95	2.68	1.28	1.11	1.18	0.77	0.43
	Earnings	(6.80)	(5.20)	(10.50)	(5.40)	(3.54)	(2.03)	(2.74)	(1.82)	(2.32)	(3.17)
	Cash flow	(5.16)	(5.80)	(2.66)	(5.44)	(1.12)	(1.74)	(1.74)	0.05	(2.24)	(3.28)
	Capex	0.00	0.00	0.00	(0.02)	(0.03)	(0.01)	(0.06)	(0.09)	(0.07)	(0.04)
	Free cash flow	(5.16)	(5.80)	(2.66)	(5.46)	(1.15)	(1.75)	(1.80)	(0.04)	(2.31)	(3.32)
	Book value	6.60	3.77	4.42	0.80	1.44	6.41	2.58	6.85	5.98	4.18
	Shares, m	3	4	9	10	13	29	37	39	56	73
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	8.52	6.27	46.40	7.94	2.45	9.53	3.29	19.04	9.69	42.66
	P/B	4.10	4.99	3.78	19.41	4.56	1.91	1.41	3.29	1.25	4.37
	EV/Sales	6.05	4.64	37.37	9.19	2.27	4.81	0.76	12.60	1.92	34.01
	EV/FCF	(1.61)	(1.14)	(4.10)	(3.29)	(5.29)	(3.52)	(0.47)	(360.53)	(0.64)	(4.39)
Cash, $m
Cash, $m	Operating cash flow	(16)	(20)	(23)	(57)	(14)	(50)	(65)	2	(126)	(240)
	Capex	0	0	0	0	0	0	(2)	(3)	(4)	(3)
	Free cash flow	(16)	(20)	(23)	(57)	(15)	(50)	(67)	(2)	(130)	(243)
Balance, $m
Balance, $m	Working capital	25	12	26	30	48	214	138	282	334	292
	Total debt	—	—	18	48	39	37	40	—	—	—
	Net debt	(29)	(17)	(28)	25	(6)	(174)	(105)	(331)	(371)	(306)
	Shareholders’ equity	21	13	38	8	19	184	96	266	337	306
Returns, %
Returns, %	ROA	(68.15)	(98.97)	(119.38)	(75.15)	(55.13)	(32.90)	(46.09)	(26.44)	(33.83)	(59.29)
	ROIC	0.00	0.00	0.00	(88.45)	(189.54)	(339.83)	0.00	0.00	0.00	(563,504.63)
	ROE	(103.19)	(138.61)	(362.69)	(247.12)	(337.87)	(57.58)	(72.84)	(39.04)	(43.42)	(72.19)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OCGN Ocugen, Inc.	$275.9M	— (loss-making)	— (loss-making)	+8.38% (above 0%: growing)	n/m	−13.42% (below 0%: shrinking)	100.00%	(1,105.11%)	Compare
NAUT Nautilus Biotechnology, Inc.	$274.9M	— (loss-making)	—	—	n/m	−3.16% (below 0%: shrinking)	92.11%	(8,296.32%)	Compare
IPSC Century Therapeutics, Inc.	$271.6M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
Median of peers	$267.1M	—	—	+285.74%	—	+5.30%	96.06%	(228.53%)

All 614 Biotechnology stocks →

EyePoint, Inc. (EYPT) key facts

Concern: EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024.
EyePoint, Inc. (EYPT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, EYPT traded at $3.00, a market capitalization of $270.7 million.
Return on equity was −72.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 8.46 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.